Clinical Outcomes with Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) Stratified By Transfusion Status: A Pooled Analysis of the COMFORT-I and -II Trials

MLA

Gupta, Vikas, et al. “Clinical Outcomes with Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) Stratified By Transfusion Status: A Pooled Analysis of the COMFORT-I and -II Trials.” Blood, vol. 128, no. 22, Dec. 2016, p. 3118. EBSCOhost, https://doi.org/10.1182/blood.V128.22.3118.3118.

APA

Gupta, V., Verstovsek, S., Paquette, R., Gotlib, J. R., Vannucchi, A. M., Kiladjian, J.-J., Cervantes, F., Sun, W., Gao, J., Langmuir, P., Gopalakrishna, P., & Harrison, C. N. (2016). Clinical Outcomes with Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) Stratified By Transfusion Status: A Pooled Analysis of the COMFORT-I and -II Trials. Blood, 128(22), 3118. https://doi.org/10.1182/blood.V128.22.3118.3118

Chicago

Gupta, Vikas, Srdan Verstovsek, Ronald Paquette, Jason R. Gotlib, Alessandro M. Vannucchi, Jean-Jacques Kiladjian, Francisco Cervantes, et al. 2016. “Clinical Outcomes with Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) Stratified By Transfusion Status: A Pooled Analysis of the COMFORT-I and -II Trials.” Blood 128 (22): 3118. doi:10.1182/blood.V128.22.3118.3118.